Gene Therapy Approaches Using Reproducible and Fully Penetrant Lentivirus-Mediated Endogenous Glioma Models - Gene Delivery and Therapy for Neurological Disorders - page 343

Table 1
Summary of endogenous rodent models of human GBM induced by expression of oncogenes and/or knockdown of tumor suppressor genes

Best
combined
penetrance

Proliferation (RTK/
KRAS/PI3K)

Apoptosis
(p53/ARF)

Cell cycle
(Rb/INK4) Author (reference) Animal System Age/injection site

Holland et al. 2000 [ 13 ] Mice RCAS Neonatal/R frontal AKT, KRAS 26 %

Dai et al. 2001 [ 9 ] Mice RCAS Neonatal/R frontal PDGF INK4a 70 %

Uhrbom et al. 2002 [ 16 ] Mice RCAS n/a KRAS ARF INK4a 42 %

Dai et al. 2005 [ 10 ] Mice RCAS n/a PDGF, KRAS, AKT n/a

Hambardzumyan
et al. 2009 [ 12 ]

Mice RCAS 4-6.5 weeks PDGF p53, ARF INK4a 100 %

Assanah et al. 2006 [ 8 ] Rats Retrovirus Adults/corpus callosum PDGF 100 %

Lei et al. 2011 [ 14 ] Mice Retrovirus Adults/white matter PDGF, PTEN p53 100 %

Wiesner et al. 2009 [ 17 ] Mice Sleeping Beauty neonatal/R lateral ventricle NRAS, SV40-LgT,

AKT

p53 100 %

Marumoto et al. 2009 [ 15 ] Mice Lentivirus 8-16 weeks/hippocampus HRAS, AKT p53 100 %

de Vries et al. 2010 [ 11 ] Mice Lentivirus 8-16 weeks/cortex KRAS p53 INK4a 100 %

Lynes et al. 2013 [ 29 ] Rats Lentivirus 7-10 weeks/cortex PDGF, HRAS, AKT 100 %